Actinium-225 is a ground-breaking new medical isotope that has shown remarkable potential to treat late-stage prostate cancer, but limited supply is holding back clinical trials and pharmaceutical research- that is, until now.
At the 11th International Conference on Isotopes (11ICI) in Saskatoon last week (July 26th), CNL’s President and CEO, Joe McBrearty announced an agreement with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Inc. (Fedoruk Centre), that will significantly increase the global supply of Actinium-225.
CNL will develop and supply targets that will be irradiated by the Fedoruk Centre and returned to CNL for further processing, and then shipped off to another long-term partner, ITM in Germany, for refinement and distribution.
The partnership will significantly increase the annual global supply of Actinium-225, enabling continued research and clinical trials.
CNL expects to produce more than 30 times the Actinium-225 that it does today.
The agreement with the Fedoruk Centre is intended to serve as an interim step that will bring much-needed supply to the international market.
By Rick Stow